This article is more than 5 years old. Information may no longer be current.
Both slow, fast travoprost delivery systems sustain IOP reduction
Click Here to Manage Email Alerts
NEW YORK — Patients with glaucoma who were treated with either a fast-elution or slow-elution rate travoprost intraocular implant experienced a 30% reduction in IOP out to 1 year, according to a poster presentation here.
“Even at 1 year with this implant in the eye releasing travoprost, the average pressure reduction was 32%. The point of this was not to demonstrate superiority of travoprost over timolol, but to show the safety of this implant in the eye, which we very well demonstrated. Of interest, there was no significant hyperemia, so it shows that the hyperemia is probably from the eye drop going on the surface of the eye, where if you put the medicine inside the eye that doesn’t happen,” Steven R. Sarkisian Jr., MD, who presented the poster, told Healio.com/OSN.
The phase 2 trial included 1:1:1 randomization of 154 patients to a fast-elution rate travoprost implant (iDose-fast, Glaukos) plus placebo eye drops twice daily arm, a slow-elution rate travoprost implant (iDose-slow) plus placebo eye drops twice daily arm, or sham surgery plus topical timolol twice daily. Fifty-four patients were included in the iDose-slow group, 51 patients in the iDose-fast group and 49 in the timolol group.
At 3 months, all three groups experienced at least a 30% reduction in IOP, but the timolol group required rescue medication to achieve this level, Sarkisian noted.
The average IOP reduction in the iDose-fast and iDose-slow groups at 1 year ranged from 32% to 33%, he said.
“All these sustained-release mechanism or techniques, they’re going to consume the ophthalmic world for the sake of our patients. It’s really exciting times,” he said. – by Robert Linnehan
Reference:
Sarkisian SR, et al. Interim results of a prospective, randomized phase 2 study evaluating the safety and initial efficacy of travoprost intraocular implants. Presented at: American Glaucoma Society annual meeting; Feb. 28 to March 4, 2018; New York.
Disclosure: Sarkisian reports he is a consultant for Glaukos, Alcon, BVI, Katena, New World Medical, Santen, Allergan and Sight Sciences.